Research Paper Volume 16, Issue 1 pp 246—266

Figure 6. (A) The performance of 97 prediction models, developed using the LOOCV framework, as evaluated by their C-index across three distinct datasets. (B, C) KIRC survival models were established by LASSO regression analysis identifying 9 Purinergic genes. (D) The correlation between Purinergic gene expression levels in pan-cancer and the survival outcomes of patients. (E) KIRC patients were divided into high-risk and low-risk groups according to the median risk score, and survival analysis was performed for both groups. (F–I) ROC survival curve analysis was performed on the established KIRC model to verify the accuracy of the survival model. The AUC values for the next 3, 5, 7, and 10 years were 0.692, 0.704, 0.71, and 0.75, respectively, and an AUC greater than 0.7 is usually considered predictive. (J) Heat map demonstrating the association between Purinergic gene expression and clinicopathological features of KIRC in the high-risk versus low-risk groups of KIRC. Light blue represents the KIRC high-risk group, and light red represents the KIRC low-risk group. Red in the color bar indicates an increase in Purinergic gene expression, and green indicates a decrease in Purinergic gene expression. *** indicates P < 0.001. (K, L) Univariate and multifactorial Cox regression analysis between risk scores, clinicopathological characteristics, and overall survival in KIRC patients. (M) A nomogram based on the Purinergic gene-associated KIRC survival model can be used to calculate the survival risk of KIRC patients for the next 5, 7, and 10 years by quantifying various factors in KIRC patients.